$3250 | Single User
$6500 | Site License
$9750 | Enterprise License

Renal cell carcinoma -Epidemiology Forecast to 2027
[Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201688 | In Stock

Introduction

DelveInsight's "Renal cell carcinoma - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Renal cell carcinoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Renal cell carcinoma Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Renal cell carcinoma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Renal cell carcinoma outlook. It also includes the explanation of changing trends of epidemiology outlining the Renal cell carcinoma scenario.

Renal cell carcinoma Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Renal cell carcinoma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

• The report covers detailed overview of Renal cell carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

• The Renal cell carcinoma Report assesses the disease risk and burden and highlights the unmet needs

• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

• 10 Year Forecast

• 7MM Coverage

• Total Cases in Renal cell carcinoma

Key assessments

• Patient Segmentation in Renal cell carcinoma

• Renal cell carcinoma Risk & Burden

• Factors driving growth in a specific Renal cell carcinoma patient population

Table of Contents
for Renal cell carcinoma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Renal cell carcinoma Epidemiology Overview at a Glance

    2.1. Patient Share Distribution of Renal cell carcinoma in 2017

    2.2. Patient Share Distribution of Renal cell carcinoma in 2027

    3. Disease Background and Overview: Renal cell carcinoma

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Renal cell carcinoma in 7MM

    4.3. Total Prevalent/ Incident Patient Population of Renal cell carcinoma in 7MM – By Countries

    5. Epidemiology of Renal cell carcinoma by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.1.3. Sub-Type Specific cases of the Renal cell carcinoma *

    5.1.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.1.5. Diagnosed Cases of the Renal cell carcinoma

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.4.3. Sub-Type Specific cases of the Renal cell carcinoma*

    5.4.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.4.5. Diagnosed Cases of the Renal cell carcinoma

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.5.3. Sub-Type Specific cases of the Renal cell carcinoma*

    5.5.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.5.5. Diagnosed Cases of the Renal cell carcinoma

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.6.3. Sub-Type Specific cases of the Renal cell carcinoma*

    5.6.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.6.5. Diagnosed Cases of the Renal cell carcinoma

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.7.3. Sub-Type Specific cases of the Renal cell carcinoma*

    5.7.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.7.5. Diagnosed Cases of the Renal cell carcinoma

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.8.3. Sub-Type Specific cases of the Renal cell carcinoma*

    5.8.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.8.5. Diagnosed Cases of the Renal cell carcinoma

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Renal cell carcinoma

    5.9.3. Sub-Type Specific cases of the Renal cell carcinoma*

    5.9.4. Sex- Specific Cases of the Renal cell carcinoma*

    5.9.5. Diagnosed Cases of the Renal cell carcinoma

    6. Unmet Needs of the Renal cell carcinoma

    7. Appendix

    8. Report Methodology

    8.1. Sources

    9. DelveInsight Capabilities

    10. Disclaimer

    11. About DelveInsight

    *Indication Specific

List Of Tables
in Renal cell carcinoma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Renal cell carcinoma in 7MM

Table 2: Total Prevalent/Incident Cases of the Renal cell carcinoma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Renal cell carcinoma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Renal cell carcinoma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Renal cell carcinoma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Renal cell carcinoma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Renal cell carcinoma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Renal cell carcinoma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Renal cell carcinoma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Renal cell carcinoma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Renal cell carcinoma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Renal cell carcinoma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Renal cell carcinoma in France (2016-2027) *

Table 14: Diagnosed Cases of the Renal cell carcinoma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Renal cell carcinoma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Renal cell carcinoma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Renal cell carcinoma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Renal cell carcinoma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Renal cell carcinoma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Renal cell carcinoma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Renal cell carcinoma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Renal cell carcinoma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Renal cell carcinoma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Renal cell carcinoma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Renal cell carcinoma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Renal cell carcinoma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Renal cell carcinoma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Renal cell carcinoma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Renal cell carcinoma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Renal cell carcinoma in Japan (2016-2027)

List Of Figures, Charts and Diagrams
in Renal cell carcinoma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Renal cell carcinoma in 7MM

Table 2: Total Prevalent/Incident Cases of the Renal cell carcinoma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Renal cell carcinoma in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Renal cell carcinoma in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Renal cell carcinoma in United States (2016-2027)*

Table 6: Diagnosed Cases of the Renal cell carcinoma in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Renal cell carcinoma in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Renal cell carcinoma in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Renal cell carcinoma in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Renal cell carcinoma in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Renal cell carcinoma in France (2016-2027)

Table 12: Sub-Type Specific cases of the Renal cell carcinoma in France (2016-2027) *

Table 13: Sex- Specific Cases of the Renal cell carcinoma in France (2016-2027) *

Table 14: Diagnosed Cases of the Renal cell carcinoma in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Renal cell carcinoma in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Renal cell carcinoma in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Renal cell carcinoma in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Renal cell carcinoma in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Renal cell carcinoma in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Renal cell carcinoma in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Renal cell carcinoma in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Renal cell carcinoma in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Renal cell carcinoma in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Renal cell carcinoma in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Renal cell carcinoma in UK (2016-2027) *

Table 26: Diagnosed Cases of the Renal cell carcinoma in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Renal cell carcinoma in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Renal cell carcinoma in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Renal cell carcinoma in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Renal cell carcinoma in Japan (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201688 | DIEI0338

Number of Pages

50

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Renal Failure Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care Inc. (U.S. Renal Care) is a healthcare service provider that offers in-center...
10 May 2016 by Global Data USD $250 More Info
Market Access Impact: Renal Cell Carcinoma (US)
IntroductionMarket barriers boost net share for 6 major RCC treatments in US. Is your brand one of t...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Market Access Impact: Renal Cell Carcinoma (EU5)
IntroductionMarket barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (US)
IntroductionOpdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?O...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
Introduction4 medical affairs teams working hard to engage oncologists. Which one gets top marks? Eu...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care, Inc. (U.S. Renal Care) is a healthcare service provider that offers in-cente...
17 Mar 2016 by Global Data USD $250 More Info
NPS+ Renal Cell Carcinoma (US)
IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists ma...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
NPS+ Renal Cell Carcinoma (EU5)
IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstVi...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
Renal Cell Carcinoma: KOL Insight
IntroductionWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Ins...
01 Feb 2015 by FirstWord Pharma USD $7,900 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Renal cell carcinoma -Epidemiology Forecast to 2027 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)